Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Vincent Armenio"'
Publikováno v:
Rhode Island medical journal (2013). 105(2)
The causes of death in COVID-19 patients with cardiac injury are uncertain.We conducted a case-control study and reviewed the electronic medical record of 109 deceased COVID-19 patients with cardiac injury on admission and 32 deceased COVID-19 patien
Autor:
Vincent Armenio, Li Juan Wang, John C. Hardaway, Marissa Cunetta, Ethan A. Prince, Ashley E. Moody, Richard P. Junghans, Steven C. Katz, N. Joseph Espat, Prajna Guha
Publikováno v:
Cancer Gene Therapy. 27:341-355
Effective chimeric antigen receptor-modified T-cell (CAR-T) therapy for liver metastases (LM) will require innovative solutions to ensure efficient delivery and minimization of systemic toxicity. We previously demonstrated the safety of CAR-T hepatic
Autor:
Mirela Stancu, Vincent Armenio, Kimberly R. Jordan, Robert Knight, Ethan A. Prince, Jill E. Slansky, Prajna Guha, John C. Hardaway, Abdul Saied, Jason Laporte, Ashley E. Moody, Richard P. Junghans, Richard D. Schulick, Steven C. Katz
Publikováno v:
Journal for Immunotherapy of Cancer
In recent years, cell therapy technologies have resulted in impressive results in hematologic malignancies. Treatment of solid tumors with chimeric antigen receptor T-cells (CAR-T) has been less successful. Solid tumors present challenges not encount
Publikováno v:
American Journal of Gastroenterology. 116:S1059-S1059
Publikováno v:
Cancer Gene Therapy. 24:141-147
Melanoma has been a long-standing focal point for immunotherapy development. In this review, we explore the evolution of melanoma treatments with particular attention to the history and recent advances in melanoma immunotherapy. We also discuss novel
Autor:
Steven C, Katz, John, Hardaway, Ethan, Prince, Prajna, Guha, Marissa, Cunetta, Ashley, Moody, Li Juan, Wang, Vincent, Armenio, N Joseph, Espat, Richard P, Junghans
Publikováno v:
Cancer gene therapy. 27(5)
Effective chimeric antigen receptor-modified T-cell (CAR-T) therapy for liver metastases (LM) will require innovative solutions to ensure efficient delivery and minimization of systemic toxicity. We previously demonstrated the safety of CAR-T hepatic
Autor:
Todd Roberts, Vincent Armenio, Ashley E. Moody, Priscilla Dasilva, Steven C. Katz, Abdul Saied Calvino, Gabrielle Masse, Jason Laporte, Kapil S Meleveedu, John Miskovsky, Richa Tandon, Greg Allen, Joseph Meharg, Abd Abdelrahman, Rabih El-Bizri
Publikováno v:
Cytokine
Cytokine: X, Vol 2, Iss 4, Pp 100035-(2020)
Cytokine: X
Cytokine: X, Vol 2, Iss 4, Pp 100035-(2020)
Cytokine: X
Highlights • COVID-19 can cause a hyperinflammatory state akin to cytokine release syndrome (CRS). • Our report shows the efficacy and safety of using anti-IL-6/IL-6-R therapy in 31 patients. • Treatment at the onset of severe CRS may be the id
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-4 (2017)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background There has been a significant improvement in survival of advanced malignancies with the advent of checkpoint inhibitors. These newer treatment modalities come with a wide spectrum of unique side effects, termed immune related adverse events
Autor:
Hussain M. Naseri, Vincent Armenio, Byung M. Kim, Shiva Kumar Reddy Mukkamalla, Steven C. Katz
Publikováno v:
Journal of the National Comprehensive Cancer Network : JNCCN. 16(4)
Background: Cholangiocarcinoma (CCA) includes cancers arising from the intrahepatic and extrahepatic bile ducts. The etiology and pathogenesis of CCA remain poorly understood. This is the first study investigating both incidence patterns of CCA from
Autor:
Paula M. Fracasso, Christine Gennigens, Carol Zhao, Vincent Armenio, Linda Duska, Ignace Vergote, John Micha, Gordon J. S. Rustin, Abraham C. F. Leung, C. H. Pippitt, Agustin A. Garcia, Johanna C. Bendell, Nicholas S. Reed, Daniel Lewis Spitz, Raoudha Soufi-Mahjoubi, Graham Dark, Christopher J. Poole, Luc Y. Dirix, Emad Ibrahim
Publikováno v:
Journal of Clinical Oncology. 31:4060-4066
Purpose Etirinotecan pegol (NKTR-102) is a unique, long-acting topoisomerase-I inhibitor with prolonged systemic exposure to SN38 (7-ethyl-10-hydroxycamptothecin), the active metabolite of irinotecan. This randomized phase II trial investigated two d